In 2025, Church & Dwight ( NYSE: CHD) expects reported sales growth of approximately of 2.5% to 3.5% and volume-driven ...

Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly ...

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

Trinity Capital posted record highs in Q3, with impressive top and bottom line growth. Read what justifies a hold with ...

Google's near-term potential looks bright. Click here to read more on how AI can help improve the outlook for GOOGL stock.

We like G Mining Ventures because the mgmt. team is experienced mine builders with access to capital, a rarity among junior ...

Despite risks like geopolitical tensions and high capital expenses, TSMC's long-term vision and market leadership make it a ...

Uniti Group’s precarious financial health results in a Hold rating. Find out why UNIT stock’s merger potential is outweighed ...

We admit to being miffed by Enovix's continued volatility. So why do we say we expect big things in the future? Click here to ...

Fresenius Medical Care has seen 18.5% growth, with strong prospects. Learn why FMS stock’s fair value of $34/share makes it a ...

The Western US solar fleet is amid rapid growth, with the region being home to four of the top five markets in planned ...

Rilparencel is ProKidney’s main candidate. It is intended as a therapy that stabilizes kidneys, making it potentially useful ...